Management of the long-term intervention with pravastatin in ischaemic disease (LIPID) study after the scandinavian simvastatin survival study (4S)

EFFECTIVENESS OF INTRAVENOUS THROMBOLYTIC TREATMENT IN ACUTE MYOCARDIAL INFARCTION

1986 • 2,315 citations

Regression of Coronary Artery Disease as a Result of Intensive Lipid-Lowering Therapy in Men with High Levels of Apolipoprotein B

1990 • 2,192 citations

INFLUENCE OF PLAQUE CONFIGURATION AND STRESS DISTRIBUTION ON FISSURING OF CORONARY ATHEROSCLEROTIC PLAQUES

1989 • 1,249 citations

By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?

1994 • 1,235 citations

Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content.

1993 • 1,132 citations

Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials.

1990 • 971 citations

Ten-Year Mortality from Cardiovascular Disease in Relation to Cholesterol Level among Men with and without Preexisting Cardiovascular Disease

1990 • 834 citations

Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease.

1993 • 833 citations

Atherosclerosis or lipoprotein-induced endothelial dysfunction. Potential mechanisms underlying reduction in EDRF/nitric oxide activity.

1992 • 457 citations

Cholesterol lowering and mortality: the importance of considering initial level of risk.

1993 • 431 citations

The Value of Lowering Cholesterol after Myocardial Infarction

1990 • 427 citations

Cholesterol lowering trials in coronary heart disease: frequency of citation and outcome.

1992 • 319 citations

Incomplete lysis of thrombus in the moderate underlying atherosclerotic lesion during intracoronary infusion of streptokinase for acute myocardial infarction: quantitative angiographic observations.

1986 • 251 citations

An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence.

1990 • 247 citations

Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients

1994 • 187 citations

Trends in cardiovascular risk factors in Australia: Results from the National Heart Foundation's Risk Factor Prevalence Study, 1980‐1989

1994 • 145 citations

Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: The cholesterol and recurrent events trial (CARE)

1991 • 126 citations

Long-term prognosis after recovery from myocardial infarction: a nine year follow-up of the Perth Coronary Register.

1983 • 120 citations

Effects of long-term treatment with lovastatin on the clotting system and blood platelets

1992 • 114 citations

Transport mechanism of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors at the blood-brain barrier.

1993 • 103 citations

Protocol for a prospective collaborative overview of all current and planned randomized trials of cholesterol treatment regimens

1995 • 96 citations

Decreased in vitro oxidizability of low‐density lipoprotein in hypercholesterolaemic patients treated with 3‐hydroxy‐3‐methyIgIutaryl‐CoA reductase inhibitors

1993 • 92 citations

Elevated plasma levels of vascular endothelial cell markers in patients with hypercholesterolemia

1993 • 91 citations

Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin, and simvastatin

1994 • 67 citations

Trends in cardiovascular risk factors in Auckland, 1982 to 1987.

1990 • 15 citations

The benefits of reducing cholesterol levels: the need to distinguish primary from secondary prevention 2. Implications for heart disease prevention in Australia

1991 • 11 citations

After the meta‐analyses: a commentary on treatment of dyslipidaemia in the primary prevention of coronary heart disease*

1994 • 6 citations